Moorfields Eye Hospital

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

Retrieved on: 
Tuesday, April 2, 2024
Patient, MIB, ARI, Therapy, AAO, Research, Surgeon, Thomas Jefferson University, German Research Foundation, Chairperson, American Diabetes Association, Macular degeneration, SAB, FACS, Food, Cornell University, Empire, University, Castle Connolly Medical, Laborie (company), Publication, Emerita, AMD, FDA, Cochrane (organisation), Moorfields Eye Hospital, American Academy, Most, Consultant, Physician, Royal college, Diabetic retinopathy, Commander, Pharmaceutical industry

WATERTOWN, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of leading global ophthalmologists to its Scientific Advisory Board (SAB), co-chaired by Carl Regillo M.D., FACS, Chief of the Retina Service at Wills Eye Hospital and Charles Wykoff, M.D., Ph.D., Director of Research of Retina Consultants of Texas. The SAB additions include Usha Chakravarthy, M.B.B.S., Ph.D.; Allen Ho, M.D. FACS FASRS, and Frank Holz, M.D., F.E.B.O., F.A.R.V.O. These three world-renowned retinal specialists will support advancement of the Company’s global clinical strategy ahead of the anticipated initiation of its Phase 3 pivotal trials in wet age-related macular degeneration (wet AMD) in the second half of this year. Additionally, the Company announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the trade name, DURAVYUTM (vorolanib intravitreal insert) for the Company’s lead product candidate, EYP-1901.

Key Points: 
  • “The SAB’s strategic counsel, global expertise, and scientific knowledge will be incredibly valuable during this critical time in EyePoint’s growth and expansion.
  • Dr. Chakravarthy has authored or co-authored over 400 publications, and she is invited to lecture in the UK and abroad.
  • FACS FASRS is Attending Surgeon, Director of Retina Research and Co-Director of the Retina Service of Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University.
  • He is a Board Member of the German Ophthalmological Society, and of the Club Jules Gonin and is past president of EURETINA.

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Retrieved on: 
Monday, March 18, 2024
DAS, Retina, University, Moorfields Eye Hospital, Pathology, Oligonucleotide, Ranibizumab, Data analysis, Partnership, Business, Boehringer Ingelheim, DME, Patient, Pharming, Research, Royal College of Ophthalmologists, Cell biology, Diabetic retinopathy, C3, University College London, MBA, Eye, Johnson & Johnson, Janssen, Drug development, John Radcliffe Hospital, AMD, CLS, University of Oxford, Royal college, Geographic atrophy, Stargardt disease, DMI, Pharmaceutical industry

ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.

Key Points: 
  • ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.
  • George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer of Clearside, commented, “Victor is a well-known and well-respected retinal clinician and scientist, who is a strategically focused and visionary leader.
  • We are delighted to have him join the Clearside team.
  • “With the upcoming ODYSSEY data and extensive partnership portfolio, this is an exciting time to join Clearside.

Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments

Retrieved on: 
Monday, October 2, 2023
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Oncology, University of Southern California, Canada, Royal college, Research and development, Central nervous system, University, American Board of Ophthalmology, Retina, Education, Senior, Lysogenic cycle, Cancer, Visual impairment, Record, Life Technologies, AstraZeneca, University of Belgrade, American Board of Commissioners for Foreign Missions, Moorfields Eye Hospital, Novartis, McMaster University, Patient, VDC, RAC, Growth, Immunology, Regulatory affairs, American College, Therapy, Roche, Eye disease, Pharmaceutical industry, Microbiology, Virology, Ophthalmology

“Jill and Mark’s appointments come at an important time in Aura’s evolution as a late stage clinical development company,” said Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura.

Key Points: 
  • “Jill and Mark’s appointments come at an important time in Aura’s evolution as a late stage clinical development company,” said Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura.
  • “We have built our leadership team with experienced industry leaders who have proven track records of success with multiple drug approvals.
  • Dr. Hopkins is board certified in Ophthalmology from the American Board of Ophthalmology and the Royal College of Surgeons Canada.
  • Before joining Sanofi Genzyme, Dr. Plavsic held various technical leadership positions with AstraZeneca, Q-One Biotech, and Life Technologies.

Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease

Retrieved on: 
Monday, July 24, 2023
Therapy, Stargardt disease, Principal investigator, RBP4, Geographic atrophy, GA, Moorfields Eye Hospital, Phase 3, HIV disease progression rates, Patient, SAN, Pleasure, Adolescence, United Kingdom, FDA, DRAGON, Safety, Pharmaceutical industry, PHOENIX

Tinlarebant is an oral, once daily retinol binding protein 4 (RBP4) antagonist designed to lower levels of ocular vitamin-A based toxins implicated in STGD1.

Key Points: 
  • Tinlarebant is an oral, once daily retinol binding protein 4 (RBP4) antagonist designed to lower levels of ocular vitamin-A based toxins implicated in STGD1.
  • “Completing enrollment of all 90 adolescent subjects across 11 countries worldwide in the Phase 3 DRAGON trial marks an important milestone for our late-stage program in STGD1.
  • Topline data for Tinlarebant in the Phase 2 STGD1 study is expected in the fourth quarter of 2023 and the interim data for the Phase 3 DRAGON trial is expected by mid-2024.
  • In addition, Belite plans to have the first patient enrolled in the 2-year Phase 3 study (PHOENIX) of Tinlarebant in Geographic Atrophy (GA) in the third quarter of 2023.

Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects

Retrieved on: 
Tuesday, July 18, 2023
Seniors, Biotechnology, Pharmaceutical, Optical, General Health, Health, Consumer, Clinical Trials, Glaucoma, Abstract, ARVO, Li Ka Shing Faculty of Medicine, NR, Eye, Control, NAD, UCL Institute of Ophthalmology, Research, ChromaDex, Trial of the century, School of Clinical Medicine, University of Cambridge, Medicine, Moorfields Eye Hospital, Patient, Peripheral vision, Randomness, School, Investigative Ophthalmology & Visual Science, Optic nerve, Association for Research in Vision and Ophthalmology, Regulatory affairs, Medical device, Medical imaging, Ophthalmology

Together, the promising results from these abstracts suggest that glaucoma patients have lower cellular NAD+ levels and thus replenishing NAD+ levels with a precursor, such as nicotinamide riboside (NR), may be a potential therapeutic strategy.

Key Points: 
  • Together, the promising results from these abstracts suggest that glaucoma patients have lower cellular NAD+ levels and thus replenishing NAD+ levels with a precursor, such as nicotinamide riboside (NR), may be a potential therapeutic strategy.
  • Dr. Garway-Heath’s abstract titled “ Primary open angle glaucoma patients have lower systemic mitochondrial function, associated with lower systemic nicotinamide adenine dinucleotide (NAD) levels, compared to Controls ” observed significantly lower cellular NAD+ levels and impaired mitochondrial function in patients with primary open-angle glaucoma (POAG).
  • Further, higher NAD+ levels were strongly associated with higher mitochondrial function parameters, suggesting increased NAD+ levels are associated with improved energy production and cellular activity.
  • POAG is a condition where pressure builds inside the eye, causing damage to the optic nerve and gradual vision loss.

Tenpoint Therapeutics Launches with $70 Million Series A Financing to Reverse Vision Loss Through Engineered Cell-Based Therapeutics and In Vivo Reprogramming

Retrieved on: 
Wednesday, July 12, 2023
Biotechnology, Health, Science, Research, Optical, University, Therapy, AMD, Sofinnova, Eye, Paratriathlon, Cell, Doctor of Philosophy, ARCH Venture Partners, Regenerative medicine, Moorfields Eye Hospital, Patient, University of Washington Department of Bioengineering, Vision Institute, Capital, FDA, Patient capital, Pharmaceutical industry, Management, Ophthalmology, MD

F-Prime and Sofinnova Partners were the founding investors who supported the company’s early operational development and technology expansion.

Key Points: 
  • F-Prime and Sofinnova Partners were the founding investors who supported the company’s early operational development and technology expansion.
  • Based on these foundational achievements, Tenpoint is advancing approaches to generate specialized ocular cell types both ex vivo and in vivo.
  • “Cell-based therapeutics represent an ideal modality for degenerative ocular diseases since most vision loss results from damaged or missing tissue.
  • Vanessa King, PhD, Tenpoint’s founding CEO, led this financing of the company and will continue to support the organization as a strategic advisor.

Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data

Retrieved on: 
Thursday, May 4, 2023
Therapy, MB, Stargardt disease, UCL Institute of Ophthalmology, RBP4, Stargardt, Bachelor of Science, Belite, Moorfields Eye Hospital, Royal College of Ophthalmologists, Patient, MB BS, Adolescence, FACS, Safety, Pharmaceutical industry, Ophthalmology

SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced it will host a virtual Key Opinion Leader event on focusing on adolescent patients with Stargardt disease (STGD1) on Wednesday, May 10, 2023 at 1:00 PM Eastern Time.

Key Points: 
  • The event will feature Michel Michaelides, BSc, MB BS, MD(Res), FRCOphth, FACS (Moorfields Eye Hospital and UCL Institute of Ophthalmology) who will discuss progression of childhood-onset STGD1 and Belite Bio’s Phase 2 study evaluating the safety and efficacy of Tinlarebant (LBS-008) in adolescent STGD1 patients.
  • Tinlarebant (LBS-008) is an oral, once daily RBP4 antagonist designed to reduce the accumulation of ocular vitamin-A based toxins which have been implicated in the onset and progression of STGD1.
  • Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease designation in the U.S., and Orphan Drug Designation in the U.S. and Europe for the treatment of STGD1.
  • A live question and answer session will follow the formal presentations.

Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1

Retrieved on: 
Tuesday, April 11, 2023
Stem cell, IOB, University, Johns Hopkins Hospital, Wilmer Ophthalmological Institute, Stargardt disease, Johns Hopkins School of Medicine, Geographic atrophy, RBP4, Vitamin A, Retina, Belite, Medical school, Moorfields Eye Hospital, Professor, Principal, University of Basel, Society, Safety, Pharmaceutical industry, Ophthalmology

SAN DIEGO, April 11, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting eye diseases with significant unmet medical need, today announced it will host a virtual key opinion leader (KOL) event to discuss the RBP4 antagonist tinlarebant and its relevance in the treatment of Stargardt Disease 1.

Key Points: 
  • (Chairman of the Department of Ophthalmology, University of Basel) who will discuss the 18-month interim efficacy and safety data from Belite Bio’s Phase 2 trial evaluating tinlarebant (LBS-008) for the treatment of Stargardt disease (STGD1).
  • Tinlarebant has been granted Fast Track and Rare Pediatric Disease designations in the U.S., and orphan drug designation in the U.S. and Europe for STGD1.
  • He completed residency at Tübingen’s University Eye Hospital prior to a fellowship at Moorfields Eye Hospital & Institute of Ophthalmology in London.
  • A replay will be available approximately two hours after the event for 90 days.

Remidio's Revolutionary AI on a smartphone for Referable Diabetic Retinopathy (DR) Receives EU MDR Class II Regulatory Approval

Retrieved on: 
Thursday, February 23, 2023
Diabetes, Moorfields Eye Hospital, Paratriathlon, Smartphone, DR, Research, FDA, Health Sciences Authority, Patient, Instituto de Química Física de los Materiales, Medio Ambiente y Energía, AI, HSA, Sale, Dietary Reference Intake, Professor, Federal Food, Drug, and Cosmetic Act, Deep learning, Outline of health sciences, Physician, Medicine, Medical device

BANGALORE, India, Feb. 23, 2023 /PRNewswire/ -- Remidio has received CE mark approval for its Medios AI, to detect Referable DR. This approval closely follows the nod the AI received from Singapore's Health Sciences Authority (HSA), assuring compliance with the highest standards.

Key Points: 
  • BANGALORE, India, Feb. 23, 2023 /PRNewswire/ -- Remidio has received CE mark approval for its Medios AI, to detect Referable DR.
  • This approval closely follows the nod the AI received from Singapore's Health Sciences Authority (HSA), assuring compliance with the highest standards.
  • Dr. Divya Rao, Remidio's Medical Director & Head of AI, called the approval a 'key milestone' as the first step towards transforming global DR screening.
  • Remidio's vision to eradicate preventable blindness has led it to publish research on a device-agnostic application for Medios DR AI.

Remidio's Revolutionary AI on a smartphone for Referable Diabetic Retinopathy (DR) Receives EU MDR Class II Regulatory Approval

Retrieved on: 
Thursday, February 23, 2023
Diabetes, Moorfields Eye Hospital, Paratriathlon, Smartphone, DR, Research, FDA, Health Sciences Authority, Patient, Instituto de Química Física de los Materiales, Medio Ambiente y Energía, AI, HSA, Sale, Dietary Reference Intake, Professor, Federal Food, Drug, and Cosmetic Act, Deep learning, Outline of health sciences, Physician, Medicine, Medical device

BANGALORE, India, Feb. 23, 2023 /PRNewswire/ -- Remidio has received CE mark approval for its Medios AI, to detect Referable DR. This approval closely follows the nod the AI received from Singapore's Health Sciences Authority (HSA), assuring compliance with the highest standards.

Key Points: 
  • BANGALORE, India, Feb. 23, 2023 /PRNewswire/ -- Remidio has received CE mark approval for its Medios AI, to detect Referable DR.
  • This approval closely follows the nod the AI received from Singapore's Health Sciences Authority (HSA), assuring compliance with the highest standards.
  • Dr. Divya Rao, Remidio's Medical Director & Head of AI, called the approval a 'key milestone' as the first step towards transforming global DR screening.
  • Remidio's vision to eradicate preventable blindness has led it to publish research on a device-agnostic application for Medios DR AI.